Skip to content
Screener

Kiniksa Pharmaceuticals International, plc KNSA SG&A

SG&A at other companies

Cytokinetics logo
CytokineticsCYTK
$104.4M+58.8%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$51.55M+12.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$186.26M+44.2%
Mannkind logo
MannkindMNKD
$58.3M+84.4%
Opko Health logo
Opko HealthOPK
$52.92M-11.2%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$9.75M+4.3%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.93B+145%
Enterprise value$5.77B+157%
P/E73.6×-433×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0×0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Cost of goods sold23,57218,60344,36836,471
Collaboration expenses88,06952,418163,64696,208
Research and development40,89918,75368,37438,078
Selling, general and administrative63,86646,863125,01790,393
Total operating expenses216,406136,637401,405261,150
Income from operations27,19420,16056,46133,432
Other income, net3,9512,7177,3655,010
Income before income taxes31,14522,87763,82638,442

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's SG&A?
Kiniksa Pharmaceuticals International, plc (KNSA) reported SG&A of $63.87M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's SG&A changed year-over-year?
Kiniksa Pharmaceuticals International, plc's SG&A increased by 36.3% year-over-year, from $46.86M to $63.87M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's SG&A?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's SG&A has grown at a 22.9% compound annual growth rate (CAGR), from $85.95M to $196.27M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Kiniksa Pharmaceuticals International, plc's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude